China National Accord Medicines Gelecekteki Büyüme

Future kriter kontrolleri 1/6

China National Accord Medicines kazanç ve gelirin sırasıyla yıllık 7% ve 5.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 7.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 8.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

7.0%

Kazanç büyüme oranı

7.1%

EPS büyüme oranı

Healthcare kazanç büyümesi	23.8%
Gelir büyüme oranı	5.7%
Gelecekteki özkaynak getirisi	8.3%
Analist kapsamı	Good
Son güncelleme	30 Oct 2024

Gelecekteki son büyüme güncellemeleri

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Oct 30

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Apr 10

Recent updates

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Oct 30

China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly

Oct 10

China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement

Aug 13

Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)

Jul 12

Is China National Accord Medicines (SZSE:000028) A Risky Investment?

Jun 12

Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet

May 12

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Apr 10

China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 15

China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet

Feb 29

Kazanç ve Gelir Büyüme Tahminleri

SZSE:000028 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	85,650	1,718	N/A	1,700	6
12/31/2025	82,126	1,615	N/A	1,650	7
12/31/2024	77,511	1,485	N/A	1,680	3
9/30/2024	75,358	1,475	2,452	2,753	N/A
6/30/2024	74,876	1,512	2,073	2,380	N/A
3/31/2024	75,881	1,626	1,769	2,093	N/A
12/31/2023	75,477	1,599	2,615	2,937	N/A
9/30/2023	75,412	1,629	1,656	1,968	N/A
6/30/2023	75,702	1,643	2,674	3,005	N/A
3/31/2023	74,979	1,597	2,672	2,988	N/A
12/31/2022	73,443	1,487	2,238	2,560	N/A
9/30/2022	72,765	1,310	1,931	2,293	N/A
6/30/2022	71,324	1,269	1,098	1,467	N/A
3/31/2022	69,459	1,260	1,360	1,744	N/A
12/31/2021	68,358	1,336	1,285	1,655	N/A
9/30/2021	66,979	1,478	592	939	N/A
6/30/2021	65,643	1,500	970	1,294	N/A
3/31/2021	62,875	1,482	1,579	1,884	N/A
12/31/2020	59,649	1,402	1,209	1,503	N/A
9/30/2020	56,244	1,306	2,663	2,937	N/A
6/30/2020	54,358	1,262	2,058	2,312	N/A
3/31/2020	53,539	1,217	1,865	2,113	N/A
12/31/2019	52,787	1,268	1,761	2,013	N/A
9/30/2019	50,779	1,243	1,546	1,817	N/A
6/30/2019	47,943	1,218	1,965	2,236	N/A
3/31/2019	44,937	1,217	1,140	1,399	N/A
12/31/2018	43,122	1,211	1,067	1,323	N/A
9/30/2018	41,751	1,182	1,110	1,338	N/A
6/30/2018	41,517	1,143	N/A	1,282	N/A
3/31/2018	41,298	1,078	N/A	923	N/A
12/31/2017	41,263	1,058	N/A	1,285	N/A
9/30/2017	41,418	1,080	N/A	1,155	N/A
6/30/2017	41,211	1,084	N/A	871	N/A
3/31/2017	41,159	1,205	N/A	959	N/A
12/31/2016	41,248	1,187	N/A	1,472	N/A
9/30/2016	49,249	1,263	N/A	1,878	N/A
6/30/2016	45,568	1,199	N/A	1,839	N/A
3/31/2016	41,870	984	N/A	1,286	N/A
12/31/2015	37,819	928	N/A	1,457	N/A
9/30/2015	25,740	721	N/A	201	N/A
6/30/2015	25,155	693	N/A	136	N/A
3/31/2015	24,683	682	N/A	-189	N/A
12/31/2014	23,954	652	N/A	-797	N/A
9/30/2014	23,418	629	N/A	-369	N/A
6/30/2014	22,680	607	N/A	-258	N/A
3/31/2014	21,864	545	N/A	-70	N/A
12/31/2013	21,199	520	N/A	465	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 000028 'nin tahmini kazanç büyümesi (yıllık 7% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 000028 şirketinin kazançlarının (yıllık 7% ) CN pazarından (yıllık 26.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 000028 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 000028 şirketinin gelirinin (yıllık 5.7% ) CN pazarından (yıllık 14% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 000028 şirketinin gelirinin (yıllık 5.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 000028 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 8.3 %).

China National Accord Medicines Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Consensus EPS estimates fall by 14%

Price target decreased by 8.4% to CN¥35.86

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Price target decreased by 11% to CN¥36.44

Price target decreased by 10% to CN¥42.49

Recent updates

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS misses analyst expectations

China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly

China National Accord Medicines Corporation Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Consensus EPS estimates fall by 14%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.4% to CN¥35.86

China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement

High number of new directors

Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)

Insufficient new directors

China National Accord Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 28, 2024

China National Accord Medicines Corporation Ltd. Announces Final Cash Dividend on B Shares for the Year 2023, Payable on 27 June 2024

Is China National Accord Medicines (SZSE:000028) A Risky Investment?

Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet

China National Accord Medicines Corporation Ltd. Approves Cash Dividend for the Year 2023

Now 20% overvalued after recent price rise

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Full year 2023 earnings: EPS and revenues miss analyst expectations

China National Accord Medicines Corporation Ltd., Annual General Meeting, May 08, 2024

China National Accord Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 30, 2024

China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate

China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 17%

China National Accord Medicines Corporation Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Now 20% undervalued after recent price drop

Price target decreased by 11% to CN¥36.44

Now 22% undervalued after recent price drop

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to CN¥42.49

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 16% to CN¥42.59

Full year 2022 earnings released: EPS: CN¥3.47 (vs CN¥3.12 in FY 2021)

Investor sentiment improves as stock rises 18%

Price target increased by 7.0% to CN¥38.16

Now 21% undervalued

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings released: EPS: CN¥0.98 (vs CN¥0.96 in 2Q 2021)

China National Accord Medicines Corporation Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 17, 2022

Price target decreased to CN¥38.17

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

China National Accord Medicines Corporation Ltd. Approves Final Cash Dividend for the Year 2021

China National Accord Medicines Corporation Ltd., Annual General Meeting, Apr 22, 2022

China National Accord Medicines Corporation Ltd. Proposes Final Cash Dividend for the Year 2021

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.96 (vs CN¥0.92 in 2Q 2020)

Price target decreased to CN¥52.97

High number of new directors

Upcoming dividend of CN¥0.80 per share

First quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.58 in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: EPS CN¥3.27 (vs CN¥2.97 in FY 2019)

China National Accord Medicines Corporation Ltd. to Report Fiscal Year 2020 Results on Apr 16, 2021

New 90-day low: CN¥41.98

New 90-day low: CN¥46.01

New 90-day high: CN¥51.91

Price target raised to CN¥60.27

Third quarter earnings released

China National Accord Medicines Corporation Ltd. to Report Q3, 2020 Results on Oct 22, 2020

First half earnings released

Earnings released

China National Accord Medicines Corporation Ltd. to Report First Half, 2020 Results on Aug 29, 2020

New 90-day high - CN¥51.20

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri